STOCK TITAN

Sangrix Cancels 66,668 Shares in Investor Redemption

The cancelled shares were returned to authorized but unissued share capital, leaving 1,881,935 Class A ordinary shares outstanding.

(Neutral)
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

SANGRIX INC. (SGRX) reports that investors exercised a contractual redemption right for 66,668 Class A ordinary shares, representing all of their respective unsold shares. The shares were cancelled on September 22, 2026 and returned to authorized but unissued share capital. Following the cancellation, 1,881,935 Class A ordinary shares were issued and outstanding.

The agreements allowed investors who had not sold all their shares within 12 months after August 11, 2025 to elect to redeem a portion of the DOGE paid, by written notice within 15 business days after that anniversary. All investors delivered notices on August 20, 2026. The redemption was described as involving the return to the Company of 30 million DOGE, representing 100% of the DOGE originally paid; the original aggregate purchase price was $6,000,000. The shares were issued in a private placement, and no warrants were issued under the agreements.

Positive

  • None.

Negative

  • None.
Shares cancelled 66,668 Class A ordinary shares Cancelled September 22, 2026
Shares issued and outstanding 1,881,935 Class A ordinary shares Following cancellation
DOGE involved in redemption 30 million DOGE Representing 100% of the DOGE originally paid
Aggregate purchase price $6,000,000 For the original share issuance
redemption right financial
"exercising this right to redeem"
private placement regulatory
"issued ... in a private placement exempt from the registration requirements"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
authorized but unissued share capital financial
"returned to the Company's authorized but unissued share capital"
redeemable amount of DOGE financial
"The redeemable amount of DOGE shall be calculated"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many SGRX shares were cancelled in the redemption?

The Company cancelled 66,668 Class A ordinary shares on September 22, 2026. The shares were returned to authorized but unissued share capital, and 1,881,935 Class A ordinary shares were issued and outstanding following cancellation.

How much DOGE was involved in SGRX's share redemption?

The redemption involved 30 million DOGE, representing 100% of the DOGE originally paid. The report describes the transaction as involving the return of that DOGE to the Company.

What was the deadline for SGRX investors to exercise the DOGE redemption right?

Investors who had not sold all their shares could give written notice within 15 business days following the 12-month anniversary of August 11, 2025. All investors delivered their notices on August 20, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of September 2026

 

Commission File Number: 001-38857

 

SANGRIX INC. 

 

160 Robinson Road, 12 F,

SBF Center, Singapore 068914

T: 347-556-4747

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F x Form 40-F ¨

 

 

 

 

 

 

As previously disclosed, on August 6, 2025, the Company entered into securities purchase agreements (the “Securities Purchase Agreements”) with certain investors relating to the issuance and sale of approximately 66,668 Class A ordinary shares (as adjusted to reflect subsequent reverse splits, the “Shares”), for an aggregate purchase price of $6,000,000. The investors elected to pay the purchase price in Dogecoin (“DOGE”). The Company received 30 million DOGE. The Shares were issued on August 11, 2025 in a private placement exempt from the registration requirements of the U.S. Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof, Regulation D promulgated thereunder and/or Regulation S promulgated thereunder. No warrants were issued pursuant to the Securities Purchase Agreements.

 

Pursuant to the Securities Purchase Agreements, if an investor does not sell all of its Shares within twelve (12) months following August 11, 2025, such investor may elect to redeem a portion of the DOGE paid by it by providing written notice to the Company within fifteen (15) business days following such twelve-month anniversary, subject to the terms and conditions of the Securities Purchase Agreements. The redeemable amount of DOGE shall be calculated based on the ratio of unsold Shares to the total purchased Shares, using the formula: Redeemable DOGE = DOGE Amount × the unsold Shares / purchased Shares.

 

On August 20, 2026, all of the investors delivered written notices to the Company exercising this right to redeem an aggregate of 66,668 Class A Ordinary Shares, representing all of such investors’ respective unsold Class A Ordinary Shares, in exchange for the return to the Company of an aggregate of 30 million DOGE, representing 100% of the DOGE originally paid by such investors.

 

On September 22, 2026, the Shares were cancelled and returned to the Company’s authorized but unissued share capital. Following such cancellation, the Company has 1,881,935 Class A ordinary shares issued and outstanding.

 

The foregoing description of the redemption right and the securities purchase agreements does not purport to be complete and is qualified in its entirety by reference to the full text of the securities purchase agreements, previously filed as Exhibit 10.1 to the Company’s Report on Form 6-K filed with the Securities and Exchange Commission on August 12, 2025, which is incorporated by reference herein.

 

This report does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: September 23, 2026 SANGRIX INC.
     
  By: /s/ Jinghai Jiang
  Name: Jinghai Jiang
  Title: Chief Executive Officer, Chief Operating Officer, and Chairman of the Board

 

3

 

Keep reading